Houthis claim attack on Saudi military sites in Jazan, no Saudi confirmation

0 min read | Published on 24 Sept 2026, 08:40 PM |Updated on 24 Sept 2026, 08:40 PM

Reviewed by

Shraddha JScanX News Team

Add as a preferred
source on Google

Key Highlights

Houthis announced attacks on Saudi military sites in Jazan
Saudi authorities have not confirmed the reported strikes
No details on casualties or damage provided by the Houthis

*this image is generated using AI for illustrative purposes only.

Yemen's Houthis stated they launched attacks on Saudi military sites located in Jazan. The group announced the operation but provided no further immediate details regarding the extent of damage or casualties.

Saudi authorities have not issued any official statement confirming or denying the reported strikes as of the time of this report. The absence of confirmation leaves the actual impact of the alleged attack unverified by official sources.

Regional security implications

Jazan is a key port city in southwestern Saudi Arabia, frequently cited in regional conflict reports due to its proximity to the Yemeni border. Attacks on military infrastructure in this area represent a recurring pattern of cross-border tensions.

The situation remains fluid with no additional data available from either side regarding the specific targets hit or the defensive response employed.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the lack of immediate Saudi confirmation influence investor sentiment regarding regional stability and oil supply chains?

Will this escalation trigger a coordinated response from the US-led coalition or Gulf Cooperation Council allies?

What are the potential impacts on shipping insurance premiums and logistics routes through the Red Sea and Bab el-Mandeb strait?

Riyadh biotech summit closes with SAR 5.5 billion in deals

1 min read | Published on 17 Sept 2026, 10:16 PM |Updated on 17 Sept 2026, 10:16 PM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Summit closed with more than SAR 5 billion (USD 1.33 billion) in agreements
Deal value up sharply from more than USD 100 million in 2024
Vaccine Industrial Company's SAR 500 million facility is 85 percent complete
KAIMRC and Thermo Fisher announced a genomics Center of Excellence
Over 15,000 visitors from 57 countries attended the four-day event

*this image is generated using AI for illustrative purposes only.

The Riyadh Global Medical Biotechnology Summit concluded its fourth edition on September 17, 2026, with more than SAR 5 billion (USD 1.33 billion) in agreements, signaling accelerated investment in the Kingdom's life sciences sector.

The event saw participation from more than 15,000 visitors across 57 countries and 120 sponsors. The deal value represents a substantial increase from the more than USD 100 million generated at the 2024 edition.

Key Agreements and Investments

The summit facilitated over 40 agreements across four strategic pillars: government strategy, investment, research readiness, and capability building.

Partner	Deal/Initiative	Value/Scale
Vaccine Industrial Company	Human vaccine facility	SAR 500 million investment
Sanabil Studio & Telepath	AI and digital pathology	USD 3 million potential investment
Life Sciences Innovation Forum	Investment fund engagement	More than USD 120 million
KAIMRC & Thermo Fisher	Genomics Center of Excellence	Research collaboration

Vaccine Industrial Company confirmed that its SAR 500 million human vaccine manufacturing facility is 85 percent complete. The project spans 42,000 square meters and plans to localize up to 80 percent of the Kingdom's essential vaccine needs.

In the digital health space, Sanabil Studio by Redesign Health signed with Telepath by Tahlili for an AI and digital pathology partnership with a potential investment of USD 3 million.

Research and Talent Development

King Abdullah International Medical Research Center (KAIMRC) announced a Center of Excellence for Genomics, Proteomics, and Biobanking with Thermo Fisher Scientific. Additional research collaborations were signed with Olink, Tiziana Life Sciences, and Japan's Chiyoda Corporation.

The University Hospitals Program signed with Novo Nordisk to build clinical trial capability. King Saud University partnered with BioMe of South Korea for a microbiome joint venture, while Najran University launched the Najran Genomic Biobank Initiative.

Talent development initiatives included a partnership between KAIMRC and Rutgers University for AI research and training. Princess Nourah bint Abdulrahman University and Cellenkos launched a program for Saudi female talent in cell and gene therapy.

What the Numbers Show

The deal value at RGMBS 2026 (USD 1.33 billion) is more than 13 times higher than the USD 100 million recorded in 2024. This sharp increase suggests a shift from early-stage networking to large-scale capital deployment and infrastructure completion, evidenced by the SAR 500 million vaccine plant nearing final stages.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How will the completion of the Vaccine Industrial Company's facility impact Saudi Arabia's reliance on imported vaccines and global supply chain dynamics in the region?

What regulatory hurdles might the AI and digital pathology partnership between Sanabil Studio and Telepath face before achieving widespread clinical adoption?

To what extent will the new talent development programs, particularly for female scientists in cell and gene therapy, help retain local expertise and reduce brain drain?